VolulyteTM in Cardiac Surgery
Efficacy and Safety of Perioperative Infusion of 6 % Hydroxyethyl Starch 130/0.4 in an Isotonic Electrolyte Solution (VolulyteTM) vs. 5% HSA as Volume Replacement Therapy During Cardiac Surgery for Adult Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Vancouver General Hospital
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
- Queen Elizabeth Ii Health Sciences Centre
-
-
Ontario
-
London, Ontario, Canada
- London Health Sciences Centre
-
Toronto, Ontario, Canada
- St. Michael's Hospital
-
Toronto, Ontario, Canada
- Toronto General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male or female adult patients
- undergoing primary elective cardiac surgery applying extracorporeal circulation
- signed written informed consent
Exclusion Criteria:
- known contraindication against scheduled medication
- pre-operative acute normovolaemic haemodilution or preoperative autologous blood donation
- planned systemic hypothermia (body temperature < 30°C)
- expected time on ECC ≥ 2 hours
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Volulyte
6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
|
Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
|
|
Active Comparator: Human serum albumin
Human serum albumin (HSA 50g/L)
|
Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Calculated red blood cell loss
Time Frame: up to 3rd postoperative day
|
up to 3rd postoperative day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Haemodynamics
Time Frame: up to 3rd postoperative day
|
up to 3rd postoperative day
|
|
|
Fluid input/output
Time Frame: up to 3rd postoperative day
|
Quantity of total fluids administered and excreted or lost from beginning of anaesthesia until 3rd postoperative day
|
up to 3rd postoperative day
|
|
Use of vasoactive and inotropic drugs
Time Frame: up to 3rd postoperative day
|
Type and amount of vasoactive and inotropic drugs administered from beginning of anaesthesia until 3rd postoperative day
|
up to 3rd postoperative day
|
|
Laboratory parameters
Time Frame: up to day 28 after surgery
|
Serum creatinine concentration at day 28 after surgery
|
up to day 28 after surgery
|
|
Laboratory parameters
Time Frame: up to 3rd postoperative day
|
set of standard laboratoy parameters before surgery and postoperatively until 3rd postop day
|
up to 3rd postoperative day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: David C Mazer, St. Michael's Hospital, Department of Anaesthesia, 30 Bond Street, Toronto, Ontario, M5B 1W8, Canada
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VOLU-010-C P4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.